Targeting NF-κB and HIF-1 pathways for the treatment of cancer: Part I

Archivum Immunologiae et Therapiae Experimentalis

Volumn 59, Issue 4, 2011, Pages 289-299

  Wilczynski, Jacek ^a,b   Duechler, Markus ^c   Czyz, Malgorzata ^b  

^a Polish Mother's Health Center   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

Author keywords

Cancer; NF B inhibitors; Treatment

Indexed keywords

BIOCURCUMAX; BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLOOXYGENASE 2; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FISETIN; FLUOROURACIL; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1; I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PINITOL; PROTEASOME INHIBITOR; SALAZOSULFAPYRIDINE; SALINOSPORAMIDE A; SULINDAC; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; CELL PROLIFERATION; CHRONIC INFLAMMATION; COLITIS; COLORECTAL CANCER; DRUG POTENTIATION; DRUG TARGETING; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FATIGUE; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INHIBITION KINETICS; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN DEGRADATION; RASH; RECTUM CANCER; REVIEW; RISK REDUCTION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; MICE; MODELS, BIOLOGICAL; NEOPLASMS; NF-KAPPA B; PYRAZINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959611207     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0131-4     Document Type: Review

References (124)

1. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208
2. Aggarwal S, Ichikawa H, Takada Y et al (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and akt activation. Mol Pharmacol 69:195-206 (Pubitemid 43048906)
3. Aggarwal BB, Vijayalekshmi RV, Sung B (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15:425-430
4. Ahn KS, Sethi G, Aggarwal BB (2007) Nuclear factor-kappaB: from clone to clinic. Curr Mol Med 7:619-637
5. Anderson KN, Bejcek BE (2008) Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB. J Pharmacol Sci 106:318-320 (Pubitemid 351366353)
6. Annunziata CM, Davis RE, Demchenko Y et al (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12:115-130 (Pubitemid 47199123)
7. Antony B, Merina B, Iyer VS et al (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70:445-449
8. Aragon-Ching JB, Li H, Gardner ER et al (2007) Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2:167-174 (Pubitemid 46952433)
9. Awada A, Albanell J, Canney PA et al (2008) Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 98:1500-1507 (Pubitemid 351652337)
10. Bachmeier BE, Mohrenz IV, Mirisola V et al (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29:779-789 (Pubitemid 351494166)
11. Bassères DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830 (Pubitemid 44657854)
12. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40
13. Beg AA, Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782-784 (Pubitemid 26398258)
14. Berenson J, Yang H, Swift R et al (2004) A Phase I/II trial of VELCADE and melphalan combination therapy (Vc + M) for patients with relapsed or refractory multiple myeloma (MM). Blood 104:164a
15. Birle DC, Hedley DW (2007) Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 67:1735-1743 (Pubitemid 46383400)
16. Bork PM, Schmitz ML, Kuhnt M et al (1997) Sesquiterpene lactone containing Mexican Indian medicinal plants and pure sesquiterpene lactones as potent inhibitors of transcription factor NF-kappaB. FEBS Lett 402:85-90 (Pubitemid 27056030)
17. Boyar MS, Hesdorffer M, Keohan ML et al (2008) Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma 2008:412503
18. Chen YC, Shen SC, Lee WR et al (2002) Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76:351-359
19. Cohen AN, Veena MS, Srivatsan ES et al (2009) Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 135:190-197
20. Culver C, Sundqvist A, Mudie S et al (2010) Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol 30:4901-4921
21. Czyz M, Lesiak-Mieczkowska K, Koprowska K et al (2010) Cell context-dependent activities of parthenolide in primary and metastatic melanoma cells. Br J Pharmacol 160:1144-1157
22. D'Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085 (Pubitemid 24139577)
23. Dahut WL, Aragon-Ching JB, Woo S et al (2009) A phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49:650-660
24. Davies AM, Chansky K, Jr1 Lara PN et al (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group study (S0339). J Thorac Oncol 4:87-92
25. Davis NB, Taber DA, Ansari RH et al (2004) Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago Phase II consortium study. J Clin Oncol 22:115-119
26. Denlinger CE, Rundall BK, Keller MD et al (2004) Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78:1207-1214 (Pubitemid 39303836)
27. Dey A, Wong ET, Cheok CF et al (2008) R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15:263-273
28. Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499
29. Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508-515 (Pubitemid 39349589)
30. Din FVN, Dunlop MG, Stark LA (2004) Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis. Br J Cancer 91:381-388 (Pubitemid 39037087)
31. Din FV, Stark LA, Dunlop MG (2005) Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency. Br J Cancer 92:1137-1143 (Pubitemid 40546681)
32. Dredge K, Marriott JB, Todryk SM et al (2002) Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 168:4914-4919 (Pubitemid 34495953)
33. Duechler M, Stańczyk M, Czyz M et al. (2008) Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells. Cancer Chemother Pharmacol 61:727-237
34. Dy GK, Thomas JP, Wilding G et al (2005) A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 11:3410-3416
35. Fan Y, Dutta J, Gupta N et al (2008) Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223-250
36. Fei XF, Wang BX, Li TJ et al (2003) Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94:92-98 (Pubitemid 36575865)
37. Figg WD, Dahut W, Duray P et al (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893 (Pubitemid 32994822)
38. Fleming IN, Hogben M, Frame S et al (2008) Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Clin Cancer Res 14:4326-4335
39. Frankel A, Man S, Elliott P et al (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728
40. Frelin C, Imbert V, Griessinger E et al (2005) Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105:804-811 (Pubitemid 40070768)
41. Fujita J, Mestre JR, Zeldis JB et al (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7:3349-3355 (Pubitemid 33069965)
42. García MG, Alaniz L, Lopes EC et al (2005) Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 29:1425-1434 (Pubitemid 41562245)
43. García-Piñeres AJ, Castro V, Mora G et al (2001) Cysteine 38 in p65/NF-kappaB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J Biol Chem 276:39713-39720
44. Gasparian AV, Guryanova OA, Chebotaev DV et al (2009) Targeting transcription factor NF-kappaB. Cell Cycle 8:1559-1566
45. Gatto S, Scappini B, Pham L et al (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Ablpositive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88:853-863 (Pubitemid 37128085)
46. Ghosh S, Hayden MS (2008) New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8:837-848
47. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(suppl):S81-S96
48. Gilmore TD, Herscovitch M (2006) Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25:6887-6899 (Pubitemid 44657858)
49. Gordon JN, Trebble TM, Ellis RD et al (2005) Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54:540-545 (Pubitemid 40403032)
50. Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950-1961 (Pubitemid 33115003)
51. Gurova K (2009) New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncol 5:1685-1713
52. Gurova KV, Hill JE, Guo C et al (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102:17448-17453 (Pubitemid 41740886)
53. Guzman ML, Rossi RM, Karnischky L et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105:4163-4169 (Pubitemid 40720758)
54. Haddad AQ, Venkateswaran V, Viswanathan L et al (2006) Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 9:68-76 (Pubitemid 43378873)
55. Hideshima T, Richardson P, Chauhan D et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076 (Pubitemid 32691956)
56. Hideshima T, Ikeda H, Chauhan D et al (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114:1046-1052
57. Hill DS, Martin S, Armstrong JL et al (2009) Combining the ER-stress inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma. Clin Cancer Res 15:1192-1198
58. Höpfner M, Schuppan D, Scherübl H (2008) Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1-14
59. Israël A (2010) The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2:a000158
60. Jagannath S, Wolf JL, Camacho E et al (2005) Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783 (Pubitemid 40904528)
61. Jandial DD, Farshchi-Heydari S, Larson CA et al (2009) Enhanced delivery of cisplatin to intraperitoneal ovariancarcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin Cancer Res 15:553-560
62. Karin M (2008) The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 18:334-342
63. Keifer JA, Guttridge DC, Ashburner BP et al (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382-22387
64. Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84:1188-1192 (Pubitemid 32511336)
65. Kondagunta GV, Drucker B, Schwartz L et al (2004) Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22:3720-3725 (Pubitemid 41095212)
66. Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36-46
67. Kraemer A, Hauser S, Kim Y et al. (2009) Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger Med Sci 7:Doc04
68. Kubicek GI, Werner-Wasik M, Machtay M et al (2009) A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for CNS malignancies. Int J Radiat Oncol Biol Phys 74:433-439
69. Kunnumakkara AB, Ichikawa H, Anand P et al (2008) Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-kappaB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis. Mol Cancer Ther 7:3306-3317
70. LeBlanc R, Catley LP, Hideshima T et al (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000 (Pubitemid 34984425)
71. Lee CH, Jeon YT, Kim SH et al (2007) NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29:19-35 (Pubitemid 46985299)
72. Li J, Cheng Y, Qu W (2011) Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol 108:84-93
73. Lieu C, Chow L, Pierson AS et al (2009) A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 27:53-62
74. Lilenbaum R, Wang X, Gu L et al (2009) Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 27:4487-4491
75. Lu X, Jung J, Cho HJ et al (2005) Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 135:2884-2890 (Pubitemid 43156558)
76. Ludwig H, Khayat D, Giaccone G et al (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794-1807 (Pubitemid 41513161)
77. Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115:2625-2632 (Pubitemid 41434385)
78. McMeekin DS, Sill MW, Benbrook D et al (2007) A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group Study. Gynecol Oncol 105:508-516 (Pubitemid 46591977)
79. Menéndez S, Higgins M, Berkson RG et al (2003) Nuclear export inhibitor leptomycin B induces the appearance of novel forms of human Mdm2 protein. Br J Cancer 88:636-643 (Pubitemid 36363376)
80. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525-4530 (Pubitemid 34627223)
81. Mitsiades CS, McMillin D, Kotoula V et al (2006) Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013-4021 (Pubitemid 44536879)
82. Mitsiades CS, Hideshima T, Chauhan D et al (2009) Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib. Semin Hematol 46:166-175
83. Mulligan G, Mitsiades C, Bryant B et al (2007) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 109:3177-3188 (Pubitemid 46572502)
84. Mutka SC, Yang WQ, Dong SD et al (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510-517
85. Naugler WE, Karin M (2008) NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18:19-26
86. Neznanov N, Gorbachev AV, Neznanova L et al (2009) Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle 8:3960-3970
87. O'Connor OA, Wright J, Moskowitz C et al (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684 (Pubitemid 46237441)
88. O'Neil BH, Raftery L, Calvo BF et al (2010) A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 9:119-125
89. Orlowski RZ, Voorhees PM, Garcia RA et al (2005) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058-3065
90. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866
91. Perkins ND (2004) NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14:64-69
92. Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466 (Pubitemid 39329586)
93. Puduvalli VK, Giglio P, Groves MD et al (2008) Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10:216-222
94. Ramsay AG, Gribben JG (2009) Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 94:1198-1202
95. Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11:495-510
96. Richardson PG, Chanan-Khan A, Schlossman RL et al (2004) Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma (MM). Blood 104:100a
97. Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464
98. Robe PA, Bentires-Alj M, Bonif M et al (2004) In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 10:5595-5603
99. Roberts BJ, Hamelehle KL, Sebolt JS et al (1986) In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114, 721). Cancer Chemother Pharmacol 16:95-101
100. Rodriguez MS, Thompson J, Hay RT et al (1999) Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation. J Biol Chem 274:9108-9115 (Pubitemid 29164718)
101. Saadane A, Masters S, DiDonato J et al (2007) Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 36:728-736 (Pubitemid 46871428)
102. Scheidereit C (2006) IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25:6685-6705
103. Schönthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 97:1465-1468
104. Scortegagna M, Cataisson C, Martin RJ et al (2008) HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 111:3343-3354
105. Sethi G, Ahn KS, Sung B et al (2008a) Pinitol targets nuclear factor-κB activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis. Mol Cancer Ther 7:1604-1614
106. Sethi G, Sung B, Aggarwal BB (2008b) Nuclear factor-κB activation: from bench to bedside. Exp Biol Med 233:21-31
107. Shankar S, Ganapathy S, Chen Q et al (2008) Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer 7:16-29
108. Shen RR, Hahn WC (2011) Emerging roles for the non-canonical IKKs in cancer. Oncogene 30:631-641
109. Shishodia S, Aggarwal BB (2004) Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol 68:1071-1080
110. Shishodia S, Koul D, Aggarwal BB (2004) Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NFkappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 173:2011-2022 (Pubitemid 38971638)
111. Sung B, Pandey MK, Aggarwal BB (2007) Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol Pharmacol 71:1703-1714 (Pubitemid 47010923)
112. Sung B, Kunnumakkara AB, Sethi G et al (2009) Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 8:959-970
113. Swamy MV, Herzog CR, Rao CV (2003) Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 63:5239-5242 (Pubitemid 37139836)
114. Takada Y, Aggarwal BB (2004) Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279:4750-4759 (Pubitemid 38199070)
115. Takada Y, Bhardwaj A, Potdar P et al (2004) Nonsteroidal antiinflammatory agents differ in their ability to suppress NFkappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23:9247-9258 (Pubitemid 40069695)
116. Takada Y, Kobayashi Y, Aggarwal BB (2005) Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IκBα kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 280:17203-17212 (Pubitemid 41389187)
117. Tergaonkar V, Correa RG, Ikawa M et al (2005) Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. Nat Cell Biol 7:921-923 (Pubitemid 41486295)
118. Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115-122 (Pubitemid 41820645)
119. Wang D, Veena MS, Stevenson K et al (2008) Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res 14:6228-6236
120. Wen J, You KR, Lee SY et al (2002) Oxidative stress-mediated apoptosis the anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 277:38954-38964 (Pubitemid 35154761)
121. Wilczynski JR, Duechler M (2010) Immunotherapy for epithelial ovarian cancer - immunological background, critical review of methods and future perspectives. Curr Immunol Rev 6:221-223
122. Williams S, Pettaway C, Song R et al (2003) Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2:835-843
123. Zangari M, Barlogie B, Hollmig K et al (2004) Marked activity of Velcade plus thalidomide (V + T) in advanced and refractory multiple myeloma (MM). Blood 104:413a-414a
124. Zhou J, Zhang H, Gu P et al (2008) NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111:419-427